Financial Results & Reports

ViroGates’ current and previous financial results, reports, analyst presentations, IPO documents, and more, are listed below.

Annual Report 2023

2023 was undoubtedly a very challenging year for ViroGates. We saw recurring revenue from COVID-19 customers disappear alongside the pandemic. We were disappointed that we could not convert COVID-19 customers to using our products in general triage in the emergency departments. These challenges affected our performance, and we landed at the lowest revenue level in three years. We adjusted our business by way of also targeting the longevity segment, and we expect shorter sales cycles in this segment of the market. The rights emission in late 2023 strengthened our cash position, and we look forward to leveraging these funds to drive growth in 2024 in both general health and acute care.

Click here to download ViroGates’ Annual Report 2023.

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates